Corvus Pharmaceuticals Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
37
- Stock Symbol
-
CRVS
- Investments
-
1
- Share Price
-
$10.64
- (As of Friday Closing)
Corvus Pharmaceuticals General Information
Description
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
Contact Information
Website
corvuspharma.comCorporate Office
- 901 Gateway Boulevard
- Suite 102
- South San Francisco, CA 94080
- United States
Corporate Office
- 901 Gateway Boulevard
- Suite 102
- South San Francisco, CA 94080
- United States
Corvus Pharmaceuticals Stock Performance
As of 13-Nov-2026, Corvus Pharmaceuticals’s stock price is $10.64. Its current market cap is $898M with 84.4M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $10.64 | $10.62 | $6.39 - $26.95 | $898M | 84.4M | 1.03M | -$0.72 |
Corvus Pharmaceuticals Financials Summary
As of 30-Sep-2026, Corvus Pharmaceuticals has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 754,573 | 510,372 | 302,479 | 55,830 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (70,475) | (17,683) | (64,032) | (28,462) |
| Net Income | (64,315) | (15,283) | (62,293) | (27,029) |
| Total Assets | 223,878 | 71,119 | 68,907 | 45,553 |
| Total Debt | 632 | 937 | 1,122 | 1,374 |
Corvus Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Corvus Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Corvus Pharmaceuticals Comparisons
Industry
Financing
Details
Corvus Pharmaceuticals Competitors (51)
One of Corvus Pharmaceuticals’s 51 competitors is Aura Biosciences, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aura Biosciences | Formerly VC-backed | Boston, MA | ||||
| Arcus Biosciences | Formerly VC-backed | Hayward, CA | ||||
| Marker Therapeutics | Formerly VC-backed | Houston, TX | ||||
| Marengo Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA |
Corvus Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Corvus Pharmaceuticals Patents
Corvus Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025221958-A1 | Adenosine a2a receptor antagonists to treat rem sleep behavior disorder and prevent synucleinopathies | Pending | 17-Apr-2024 | ||
| WO-2025171035-A1 | Itk inhibitors and uses thereof | Pending | 06-Feb-2024 | ||
| EP-4828748-A1 | Use of itk inhibitors and car t-cell therapy | Pending | 18-Dec-2023 | ||
| WO-2025137059-A1 | Use of itk inhibitors and car t-cell therapy | Inactive | 18-Dec-2023 | ||
| EP-4794694-A1 | Interleukin-2-inducible t-cell kinase inhibitors to produce enhanced immune responses | Pending | 20-Oct-2023 | A61K45/06 |
Corvus Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Corvus Pharmaceuticals Investments (1)
Corvus Pharmaceuticals’s most recent deal was a Later Stage VC with Angel Pharmaceuticals for . The deal was made on 10-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Angel Pharmaceuticals | 10-Jun-2026 | Later Stage VC | Drug Discovery |
Corvus Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
40.94 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Corvus Pharmaceuticals Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Angel Pharmaceuticals | Jiaxing, China | 2020 |
Corvus Pharmaceuticals FAQs
-
When was Corvus Pharmaceuticals founded?
Corvus Pharmaceuticals was founded in 2014.
-
Where is Corvus Pharmaceuticals headquartered?
Corvus Pharmaceuticals is headquartered in South San Francisco, CA.
-
What is the size of Corvus Pharmaceuticals?
Corvus Pharmaceuticals has 37 total employees.
-
What industry is Corvus Pharmaceuticals in?
Corvus Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Corvus Pharmaceuticals a private or public company?
Corvus Pharmaceuticals is a Public company.
-
What is Corvus Pharmaceuticals’s stock symbol?
The ticker symbol for Corvus Pharmaceuticals is CRVS.
-
What is the current stock price of Corvus Pharmaceuticals?
As of 13-Nov-2026 the stock price of Corvus Pharmaceuticals is $10.64.
-
What is the current market cap of Corvus Pharmaceuticals?
The current market capitalization of Corvus Pharmaceuticals is $898M.
-
Who are Corvus Pharmaceuticals’s competitors?
Aura Biosciences, Arcus Biosciences, Marker Therapeutics, Marengo Therapeutics, and Kite Pharma are some of the 51 competitors of Corvus Pharmaceuticals.
-
What is Corvus Pharmaceuticals’s annual earnings per share (EPS)?
Corvus Pharmaceuticals’s EPS for 12 months was -$0.72.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
